I just got back from Advanced Technologies & Treatments for Diabetes (ATTD) ,the world’s biggest diabetes tech conference, and this was a HUGE year for tech innovation and news. From accuracy updates on the 15-day Dexcom G7 to more information on the soon-to-be-released twiist pump, I’ve got a lot to cover, so let’s get to it!
The twiist pump is making its way to the U.S – imminently
It’s official— the twiist insulin pump could launch as soon as next month! I met with Sequel Med Tech’s CEO, Alan Lotvin, to talk about pump’s upcoming compatibility with the Libre 3 Plus CGM to its unique occlusion detection that uses sound waves. He also tells me how people will get twiist through pharmacy benefits, making the system more accessible than other pumps. Plus, we got into the pump’s future CGM support and when we can expect twiist to expand beyond the U.S.
Tune in below for the inside scoop or listen on podcast platforms.
Want to learn more about the twiist algorithm and features? Check out my recent article here.
If you want to read this newsletter later, open it in a browser:
Kaleido 2: The smallest rechargeable pump just got an upgrade
The Kaleido 2 insulin pump made its debut at the ATTD conference, and I got to see it up close! This next-generation device is 10% smaller than its predecessor and sports a sleek, matte finish in six stylish colors. With new features like an accelerometer—potentially enabling activity tracking—and a temperature sensor to help protect your insulin, Kaleido 2 marks an exciting leap forward in diabetes technology.
Get the full scoop on this upcoming pump—including when it might arrive in the U.S.—in my latest blog post!
LIVE from Amsterdam, all the latest news from ATTD!
While in Amsterdam, I had to take the opportunity to record an update on all the latest in diabetes tech. On my most recent podcast episode, endocrinologist and fellow diabetes tech nerd, Dr. David Ahn, and I break down the biggest diabetes tech announcements from this year’s conference—and trust me, there’s a lot to be excited about.
We kick things off by discussing:
Dexcom G7 15-day sensor : The updated CGM has better accuracy (MARD).
Tandem’s Control-IQ+ updates: The new algorithm offers automated Temp Basal adjustments, an extended Extended Bolus and expanded indications.
TITR vs TING: A controversial conversation about “normal” glycemic range.
Tune into the episode now on all major platforms or on Youtube (below) to get the full scoop on how these innovations are transforming the future of diabetes technology.
Tandem’s Control-IQ+ update could make management easier
Tandem Diabetes released an updated algorithm bringing powerful new features that make diabetes management simpler and more effective. With expanded eligibility, smarter insulin delivery, and a streamlined setup, the system is now more accessible and user-friendly than ever. The algorithm also expands access to those with Type 2 diabetes and children as young as 2 years old.
Here’s what’s new:
Extended Basal for up to 8 hours.
Temp Basal while in automated mode to help manage short-term needs during exercise, stress, or illness.
Simplified setup: The t:slim X2 now only requires weight and TDI for easier onboarding—with a new Spanish-language option.
Learn all about the Control-IQ+ updates in latest article to discover how these updates could help you and how I am already taking advantage of them…
P.S did I mention I’m trialing Mobi for the next three months? Stay tuned for my full review ;)
Healthcare professionals, this one’s for you!
Are you a doctor, nurse, diabetes educator, or healthcare professional working in diabetes care? Your insights are invaluable—and now, you can get paid to share them!
Thrivable is looking for HCPs to participate in exclusive, paid research studies that help shape the future of diabetes technology, treatment, and patient care. Here’s what to expect:
Earn up to $500 per study for your time and expertise
Help improve diabetes care by sharing your real-world clinical insights
Join a network of leading HCPs influencing the next wave of diabetes innovation
Signing up is quick and easy. Use my affiliate link and once registered, you’ll receive invitations to studies that match your background.
Product link disclosure - In order to provide free content, we use affiliate links. This means if you make purchases through certain links, we may earn a small commission (at no extra cost to you).